These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 36521007)

  • 21. SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.
    Wang S; Sun W; Zhao Y; McEachern D; Meaux I; Barrière C; Stuckey JA; Meagher JL; Bai L; Liu L; Hoffman-Luca CG; Lu J; Shangary S; Yu S; Bernard D; Aguilar A; Dos-Santos O; Besret L; Guerif S; Pannier P; Gorge-Bernat D; Debussche L
    Cancer Res; 2014 Oct; 74(20):5855-65. PubMed ID: 25145672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro.
    Burmakin M; Shi Y; Hedström E; Kogner P; Selivanova G
    Clin Cancer Res; 2013 Sep; 19(18):5092-103. PubMed ID: 23864164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic Inhibition of the MDM2-p53 Interaction Prevents Recurrence of Adenoid Cystic Carcinomas.
    Nör F; Warner KA; Zhang Z; Acasigua GA; Pearson AT; Kerk SA; Helman JI; Sant'Ana Filho M; Wang S; Nör JE
    Clin Cancer Res; 2017 Feb; 23(4):1036-1048. PubMed ID: 27550999
    [No Abstract]   [Full Text] [Related]  

  • 24. The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.
    Canon J; Osgood T; Olson SH; Saiki AY; Robertson R; Yu D; Eksterowicz J; Ye Q; Jin L; Chen A; Zhou J; Cordover D; Kaufman S; Kendall R; Oliner JD; Coxon A; Radinsky R
    Mol Cancer Ther; 2015 Mar; 14(3):649-58. PubMed ID: 25567130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells.
    Her NG; Oh JW; Oh YJ; Han S; Cho HJ; Lee Y; Ryu GH; Nam DH
    Cell Death Dis; 2018 Jul; 9(8):792. PubMed ID: 30022047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma.
    Lu J; Guan S; Zhao Y; Yu Y; Wang Y; Shi Y; Mao X; Yang KL; Sun W; Xu X; Yi JS; Yang T; Yang J; Nuchtern JG
    Oncotarget; 2016 Dec; 7(50):82757-82769. PubMed ID: 27764791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice.
    Wang W; Qin JJ; Voruganti S; Wang MH; Sharma H; Patil S; Zhou J; Wang H; Mukhopadhyay D; Buolamwini JK; Zhang R
    Gastroenterology; 2014 Oct; 147(4):893-902.e2. PubMed ID: 25016295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis.
    Sato A; Sunayama J; Matsuda K; Seino S; Suzuki K; Watanabe E; Tachibana K; Tomiyama A; Kayama T; Kitanaka C
    Stem Cells; 2011 Dec; 29(12):1942-51. PubMed ID: 21957016
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme.
    Daniele S; La Pietra V; Piccarducci R; Pietrobono D; Cavallini C; D'Amore VM; Cerofolini L; Giuntini S; Russomanno P; Puxeddu M; Nalli M; Pedrini M; Fragai M; Luchinat C; Novellino E; Taliani S; La Regina G; Silvestri R; Martini C; Marinelli L
    Eur J Pharmacol; 2021 Apr; 897():173936. PubMed ID: 33581134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of miR-18b in MDM2-p53 pathway signaling and melanoma progression.
    Dar AA; Majid S; Rittsteuer C; de Semir D; Bezrookove V; Tong S; Nosrati M; Sagebiel R; Miller JR; Kashani-Sabet M
    J Natl Cancer Inst; 2013 Mar; 105(6):433-42. PubMed ID: 23365201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
    Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ
    Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53.
    Canner JA; Sobo M; Ball S; Hutzen B; DeAngelis S; Willis W; Studebaker AW; Ding K; Wang S; Yang D; Lin J
    Br J Cancer; 2009 Sep; 101(5):774-81. PubMed ID: 19707204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors.
    Howard TP; Arnoff TE; Song MR; Giacomelli AO; Wang X; Hong AL; Dharia NV; Wang S; Vazquez F; Pham MT; Morgan AM; Wachter F; Bird GH; Kugener G; Oberlick EM; Rees MG; Tiv HL; Hwang JH; Walsh KH; Cook A; Krill-Burger JM; Tsherniak A; Gokhale PC; Park PJ; Stegmaier K; Walensky LD; Hahn WC; Roberts CWM
    Cancer Res; 2019 May; 79(9):2404-2414. PubMed ID: 30755442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.
    Endo S; Yamato K; Hirai S; Moriwaki T; Fukuda K; Suzuki H; Abei M; Nakagawa I; Hyodo I
    Cancer Sci; 2011 Mar; 102(3):605-13. PubMed ID: 21205074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting the TP53/MDM2 axis enhances radiation sensitivity in atypical teratoid rhabdoid tumors.
    Alimova I; Wang D; Danis E; Pierce A; Donson A; Serkova N; Madhavan K; Lakshmanachetty S; Balakrishnan I; Foreman NK; Mitra S; Venkataraman S; Vibhakar R
    Int J Oncol; 2022 Mar; 60(3):. PubMed ID: 35179215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of nonsense-mediated decay rescues p53β/γ isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancers.
    Gudikote JP; Cascone T; Poteete A; Sitthideatphaiboon P; Wu Q; Morikawa N; Zhang F; Peng S; Tong P; Li L; Shen L; Nilsson M; Jones P; Sulman EP; Wang J; Bourdon JC; Johnson FM; Heymach JV
    J Biol Chem; 2021 Nov; 297(5):101163. PubMed ID: 34481841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Augmented antitumor activity of 5-fluorouracil by double knockdown of MDM4 and MDM2 in colon and gastric cancer cells.
    Imanishi M; Yamamoto Y; Wang X; Sugaya A; Hirose M; Endo S; Natori Y; Yamato K; Hyodo I
    Cancer Sci; 2019 Feb; 110(2):639-649. PubMed ID: 30488540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer.
    Adams CM; Mitra R; Xiao Y; Michener P; Palazzo J; Chao A; Gour J; Cassel J; Salvino JM; Eischen CM
    Cancer Discov; 2023 May; 13(5):1210-1229. PubMed ID: 36734633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Co-transduction of ribosomal protein L23 enhances the therapeutic efficacy of adenoviral-mediated p53 gene transfer in human gastric cancer.
    Zhang YF; Zhang BC; Zhang AR; Wu TT; Liu J; Yu LF; Wang WX; Gao JF; Fang DC; Rao ZG
    Oncol Rep; 2013 Oct; 30(4):1989-95. PubMed ID: 23933826
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
    Wang H; Nan L; Yu D; Agrawal S; Zhang R
    Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.